Acta Scientific Pharmaceutical Sciences (ASPS)(ISSN: 2581-5423)

Research Article Volume 4 Issue 5

Histological Changes in Lung Induced by Single Intratracheal Instillation on Bleomycin in Wistar Rats

Ramesh Verma1, Poonam Mehta1, Vishvesh Dalal1, Manish V Patel1, Parnav Buch2, Pratyush Patankar2 and Suresh Balakrishnan2*

1Department of Toxicology, Jai Research Foundation, Valvada, Gujarat, India
2Division of Toxicology, Department of Zoology, Faculty of Science, The M.S. University of Baroda, Vadodara, Gujarat, India

*Corresponding Author: Suresh Balakrishnan, Division of Toxicology, Department of Zoology, Faculty of Science, The M.S. University of Baroda, Vadodara, Gujarat, India.

Received: March 11, 2020; Published: April 08, 2020



  The present study examined the histological changes in lung tissue induced by single intratracheal instillation on bleomycin in Wistar rats. Animals were treated with bleomycin at the dose of 6.5 U/kg body weight via., single intra-tracheal instillation. Histopathological abnormalities in lungs were assessed on day 21 using hematoxylin and eosin staining and Masson’s trichrome staining. Single intra-tracheal instillation of bleomycin led to the extensive deposition of collagen in peribronchial and perialveolar region, which obliterated the alveolar spaces. Severe lung alveolitis and injury, which was manifested with interalveolar inflammation, thickening alveolar wall, bronchial erosion, and large fibrotic area inconsistently. The results of the present study speculate that inflammation is the forerunner of fibrosis induced by single intra-tracheal instillation of bleomycin.

Keywords:Bleomycin; Lung Fibrosis



  1. Adamson IY. “Pulmonary toxicity of bleomycin”. Environmental Health Perspectives 16 (1976): 119-125.
  2. Arafa HMM., et al. “Antifibrotic effect of meloxicam in a murine lung fibrosis model”. European Journal of Pharmacology 1-3 (2007): 181-189.
  3. “American thoracic society. Idiopathic pulmonary fibrosis: Diagnosis and treatment international consensus statement”. American Journal of Respiratory and Critical Care Medicine 161 (2000): 646-664.
  4. “American thoracic society/European respiratory society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias”. American Journal of Respiratory and Critical Care Medicine 165 (2002): 277-304.
  5. Chaudhary NI., et al. “Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model”. American Journal of Respiratory and Critical Care Medicine 7 (2006): 769-776.
  6. Claussen CA and Long EC. “Nucleic acid recognition by metal complexes of bleomycin”. Chemical Reviews 9 (1999): 2797-2816.
  7. Grande NR., et al. “Lung fibrosis induced by bleomycin: Structural changes and overview of recent advances”. Scanning Microscopy 3 (1998): 487-494.
  8. Hunninghake GW., et al. “Immunologic reactivity of the lung: the in vivo and in vitro generation of a neutrophil chemotactic factor by alveolar macrophages”. The American Review of Respiratory Disease 117 (1978): 15-23.
  9. Iyer SN., et al. “Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation”. Inflammation 24 (2000): 477-491.
  10. Kim DS., et al. “Classification and natural history of the idiopathic interstitial pneumonias”. Proceedings of the American Thoracic Society 4 (2006): 285-292.
  11. Moeller A., et al. “The bleomycin animal model: A useful tool to investigate treatment options for idiopathic pulmonary fibrosis?” The International Journal of Biochemistry and Cell Biology 40 (2008): 362-382.
  12. Sebti SM., et al. “Bleomycin hydrolase: Molecular cloning, sequencing, and biochemical studies reveal membership in the cysteine proteinase family”. Biochemistry16 (1989): 6544-6548.
  13. Teixeira KC., et al. “Attenuation of bleomycin-induced lung injury and oxidative stress by N-acetylcysteine plus deferoxamine”. Pulmonary Pharmacology and Therapeutics 21 (2008): 309-316.
  14. Umezawa H. “Studies on bleomycin”. Cancer 20 (1967): 891.
  15. Verma R., et al. “Evaluating the inhibitory potential of sulindac against the bleomycin induced pulmonary fibrosis in wistar rats”. Environmental Toxicology and Pharmacology3 (2013): 769-778.
  16. Wang HD., et al. “Bilirubin ameliorates bleomycin-induced pulmonary fibrosis in rats”. American Journal of Respiratory and Critical Care Medicine 165 (2002): 406-411.
  17. Zhao L., et al. “Neferine, a bisbenzylisoquinline alkaloid attenuates bleomycin induced pulmonary fibrosis”. European Journal of Pharmacology 627 (2010): 304-312.


Citation: Suresh Balakrishnan., et al. “Histological Changes in Lung Induced by Single Intratracheal Instillation on Bleomycin in Wistar Rats". Acta Scientific Pharmaceutical Sciences 4.5 (2020): 11-14.


Acceptance rate32%
Acceptance to publication20-30 days

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is July 10, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US